A new breakthrough Alzheimer's drug is giving people hope, but the cost is raising concern among advocates.
INDIANAPOLIS -- According to the Alzheimer’s Association about 1 in 9 people ages 65 and older have Alzheimer’s. A new breakthrough is giving people hope, but the cost is raising concern.
Olivia Purevich knows first-hand how devastating the news can be to have a loved one diagnosed with Alzheimer’s. Her grandmother and father both passed away after suffering with Alzheimer’s for several years. While the new breakthrough gives Olivia hope, if she or any other of her loved ones might suffer from the disease in the future the treatment comes at a cost. The company puts the price tag at over $26,000 a year.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. FDA approves Alzheimer's drug that appears to slow rate of cognitive declineThe drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.
Read more »
FDA Approves New Alzheimer's Drug Designed to Slow Cognitive DeclineThe US Food and Drug Administration (FDA) on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.
Read more »
The FDA approves an Alzheimer's drug that appears to modestly slow the diseaseThe Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease. (Story aired on Weekend Edition Saturday on Jan. 6, 2023.)
Read more »
FDA approves Alzheimer’s drug lecanemab amid safety concernsReports of deaths potentially linked to the treatment have cast a shadow on what many hail as a landmark approval.
Read more »
Neurologist discusses FDA approval of new Alzheimer's drug | KVUEThe US_FDA has granted accelerated approval for a new drug that would slow the progression of Alzheimer's Disease in its early stages. A neurologist who has been an investigator on numerous trials related to Alzheimer's joined KVUEMidday to discuss
Read more »